Nanyang Biologics (NYB.AI) secured First Prize at the inaugural SuperAI Genesis Startup Competition, triumphing over more than 700 startups from over 100 countries. The competition, renowned for spotlighting breakthrough AI innovations, brought together top ventures from across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
Revolutionizing Drug Discovery with AI and Nature
NYB.AI stood out for its AI-driven drug discovery platform focused on nature-derived compounds and regionally relevant treatments. Its proprietary DTIGN platform (Drug‑Target Interaction Graph Neural Network) blends graph neural networks with molecular docking to predict drug-target interactions with exceptional accuracy—particularly in compounds sourced from Southeast Asia’s biodiverse flora, a domain often overlooked by Western pharma.
Breakthrough Capabilities of DTIGN Platform
As per the press release, the DTIGN platform delivers measurable advantages that make it a potential game-changer for biotech R&D:
- 25% higher accuracy than the next-best method (recognized by IEEE Magazine)
- 10× faster model training, cutting computation time from 80 to 10 hours
- 8× faster molecular docking, reducing processing time from 70 to 8 hours
- ~64× improvement in hit-rate efficiency
- 44.8% increase in bioactivity prediction accuracy
These advances dramatically accelerate drug development timelines, reduce R&D costs, and improve overall success rates.
Strategic Support from Fischer Medical Ventures
Fischer Medical Ventures Ltd (FMV)—formerly Fischer Chemic Ltd—has played a critical role as a strategic joint-venture partner in NYB.AI’s success. FMV, known for its affordable and accessible medical imaging and AI-powered healthcare software, actively supports the development of NYB.AI’s evidence-based nutraceuticals derived from Indian and Southeast Asian herbs.
FMV’s involvement strengthens NYB.AI’s mission to transform traditional botanical knowledge into globally relevant therapeutic and wellness solutions.
Rapid Commercial Momentum and Key Industry Partners
NYB.AI continues to gain commercial traction, backed by global tech and pharma leaders such as:
- NVIDIA
- Johnson & Johnson Innovation – JLABS
- Equinix
- Hewlett Packard Enterprise (HPE)
The company’s selection to present at NVIDIA’s GTC 2025 further validates its scalable technology and industry relevance.
Rooted in Research, Guided by Vision
Founded by scientists from Nanyang Technological University (NTU) with hands-on pharmaceutical R&D experience, NYB.AI combines deep academic expertise with a vision for AI-led natural drug discovery. Beyond pharmaceuticals, their platform also applies to nutraceuticals, beauty products, and animal health—opening doors to multi-sector innovation.
Judges Applaud Innovation and Global Potential
The SuperAI Genesis judging panel praised NYB.AI for its all-round excellence in:
- Innovation – Creative use of graph neural networks for discovering natural compounds
- Market Potential – Applications spanning pharma, supplements, and wellness
- Scalability – Strong infrastructure and proven partnerships across sectors
A Shared Vision: Tradition Meets Technology
Mr. Ravindran Govindan, Executive Chairman & MD of Fischer Medical Ventures Ltd, expressed his pride in the win:
“We are honoured to receive this recognition at SuperAI Genesis. This award affirms our joint commitment to unlocking the molecular secrets of Indian and Southeast Asian herbs and bringing them to the global market—faster and more affordably. We firmly believe India’s traditional medicine holds untapped treasures, and NYB.AI is poised to turn that heritage into modern, validated therapies. In fact, we have already identified a traditional Indian herb showing significant promise for mental health treatment—an exciting breakthrough.”